(2E,4E)-3-methyl-5-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclohex-1-enyl]-penta-2,4-dienoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (2E,4E)-3-methyl-5-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclohex-1-enyl]-penta-2,4-dienoic acid
• 英文别名: E,E-3-Methyl-5-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-cyclohexen-1-yl]-2,4-pentadienoic Acid；(2E,4E)-3-methyl-5-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclohexen-1-yl]penta-2,4-dienoic acid
• 化学式: C₂₆H₃₄O₂
• 分子量: 378.555
• InChiKey: APVONJDYTSBAMH-UKRGKPDNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  E,E-3-Methyl-5-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-cyclohexen-1-yl]-2,4-pentadienoic Acid Ethyl Ester 、 氢氧化钾 、 二氯甲烷 、 盐酸 在 ice 、 Sodium sulfate-III 、 乙醇 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to give 0.5 g of the desired compound as colorless crystals的产率得到(2E,4E)-3-methyl-5-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclohex-1-enyl]-penta-2,4-dienoic acid
  参考文献：
  名称：

  Restricted 9-cis retinoids

  摘要：

  该发明涉及一种新型9-顺-视黄酸类似物，可用于治疗和预防冠状动脉疾病，并通过增加高密度脂蛋白水平来保护免受早期动脉粥样硬化的影响。该发明还包括制备这种新型9-顺-视黄酸类似物的方法。

  公开号：

  US05968908A1

文献信息

• Restricted 9-cis retinoids
  申请人：American Cyanamid Company

  公开号：US05968908A1

  公开（公告）日：1999-10-19

  The invention is novel analogs of 9-cis-retinoic acid which are useful for the treatment and prevention of coronary artery disease and to protect against premature atherosclerosis by increasing HDL levels. The invention includes processes for preparing the novel 9-cis-retinoic acid analogs.

  该发明涉及一种新型9-顺-视黄酸类似物，可用于治疗和预防冠状动脉疾病，并通过增加高密度脂蛋白水平来保护免受早期动脉粥样硬化的影响。该发明还包括制备这种新型9-顺-视黄酸类似物的方法。
• Restricted 9-cis-retinoids
  申请人：American Cyanamid Company

  公开号：EP0718285A2

  公开（公告）日：1996-06-26

  The invention is novel analogs of 9-cis-retinoic acid which are useful for the treatment and prevention of coronary artery disease and to protect against premature atherosclerosis by increasing HDL levels. The invention includes processes for preparing the novel 9-cis-retinoic acid analogs.

  本发明是新型 9-顺式维甲酸类似物，可用于治疗和预防冠状动脉疾病，并通过提高高密度脂蛋白水平防止动脉粥样硬化过早发生。本发明包括制备新型 9-顺式维甲酸类似物的工艺。
• Restricted 9-cis retenoids
  申请人：American Cyanamid Company

  公开号：EP0997455A1

  公开（公告）日：2000-05-03

  The invention is novel analogs of 9-cis-retinoic acid which are useful for the treatment and prevention of coronary artery disease and to protect against premature atherosclerosis by increasing HDL levels. The invention includes processes for preparing the novel 9-cis-retinoic acid analogs.

  本发明是新型 9-顺式维甲酸类似物，可用于治疗和预防冠状动脉疾病，并通过提高高密度脂蛋白水平防止动脉粥样硬化过早发生。本发明包括制备新型 9-顺式维甲酸类似物的工艺。
• RETINOIC ACID X-RECEPTOR LIGANDS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0775103B1

  公开（公告）日：1999-06-09
• Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases
  申请人：Bollag Werner

  公开号：US20080255206A1

  公开（公告）日：2008-10-16

  The present invention relates to the use of one or more retinoid agonists and/or antagonists comprising retinoids with selective Retinoid X Receptor (RXR) agonistic or antagonistic activity alone or in combination with one or more peroxisome proliferator activated receptor (PPAR) ligands for the manufacture of a medicament for the (preferably oral or topical) treatment (this term including prevention/prophylaxis and/or therapy) of one or more manifestations of metabolic syndrome (also known as syndrome X), also called diseases hereinafter, especially from one or more manifestations thereof selected from the group consisting of diabetes type II, obesity, dyslipidemia, hypertension and polyneuropathy, each of which can also be linked with a high risk of cardiovascular diseases. Corresponding methods, the compounds and combinations for use in the treatment of the mentioned diseases and comparable invention embodiments are also described.